Bowel cancer „melted away” after immunotherapy, then stayed away
How durable is the protection from pre-surgical immunotherapy?
A short course of immunotherapy given before surgery led to complete disappearance of tumors in some patients with stage two or three bowel cancer, with no signs of return during follow-up. The results come from the NEOPRISM-CRC trial conducted by researchers at University College London, involving 32 patients treated in 2026. This approach aims to eliminate cancer cells early and prevent relapse after surgical removal.
Immunotherapy works by boosting the body’s immune system to recognize and attack cancer cells. In this trial, patients received a brief regimen of immune checkpoint inhibitors prior to surgery. Scans showed tumors vanished entirely in a subset of participants, a response described by researchers as melting away. Importantly, these patients showed no evidence of cancer recurrence during monitoring periods lasting several months after treatment.
Can this approach replace surgery for bowel cancer?
Researchers noted that the absence of cancer return in responders suggests the treatment may trigger long-term immune memory. This means the immune system could continue to patrol for cancer cells even after therapy ends. While not all patients responded, those who did had complete pathological responses, meaning no cancer cells were found in tissue removed during surgery. The trial did not specify exact survival rates but emphasized the quality and durability of response in successful cases.
Despite the dramatic tumor shrinkage, surgery remained part of the protocol in the trial. Experts caution that immunotherapy alone is not yet sufficient to remove the need for surgical intervention. However, the strong pre-surgical effect raises questions about whether future regimens could eventually minimize or alter surgical requirements, especially for patients who show early and complete response. Larger trials are needed to assess long-term outcomes and safety.
What type of immunotherapy was used in the NEOPRISM-CRC trial? The trial used immune checkpoint inhibitors, a form of immunotherapy that helps the immune system identify and attack cancer cells, though the specific drugs were not named in the source.
Frequently Asked Questions
How many patients saw their tumors disappear completely? While the exact number was not provided, a subset of the 32 patients experienced complete tumor disappearance, described as a melting awayeffect, with no cancer detected in surgical specimens.
Is this treatment available for all bowel cancer patients now? No, the approach remains experimental and was tested only in a clinical trial setting for stage two or three bowel cancer patients; wider use awaits further research and regulatory approval.